Kenneth Johnson, MD
Internal Medicine · Kinston, NCNPI 1457336760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 597 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,577 and has fallen 52.8% since, to $745 in 2025. Among internal medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 597 payments — averaging $13.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$838
- AbbVie$686
- AstraZeneca$598
- Amgen$579
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$444
- plus $3K from 33 others
Across 105 payments — averaging $1030.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$45K
- AbbVie$29K
- Genentech, Inc.$28K
- Novo Nordisk AS$4K
- Boehringer Ingelheim Canada Ltd.ltee$2K
- Eli Lilly$54
What the payments were for
- Food & beverage$7,93499%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 135 | $1,592 |
| Lilly USA, LLC | 75 | $838 |
| AbbVie(2 entities) | 56 | $686 |
| AstraZeneca | 34 | $598 |
| Amgen(2 entities) | 46 | $579 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $444 |
| Boehringer Ingelheim | 25 | $355 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $350 |
| Johnson & Johnson | 17 | $279 |
| Sanofi-aventis U.S. LLC | 15 | $228 |
| Pfizer | 20 | $228 |
| GSK | 13 | $211 |
| Merck | 13 | $208 |
| Novartis | 16 | $199 |
| Tepha Inc | 3 | $167 |
| Kowa Pharmaceuticals America, Inc. | 10 | $131 |
| Bayer | 7 | $116 |
| Mylan Specialty L.p. | 5 | $74 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| Biohaven Pharmaceuticals, Inc. | 5 | $64 |
| Phathom Pharmaceuticals, Inc. | 4 | $64 |
| Amarin Pharma, Inc. | 4 | $57 |
| Hikma Pharmaceuticals USA | 3 | $51 |
| Corium, LLC | 3 | $47 |
| Ironwood Pharmaceuticals, Inc | 3 | $40 |
| Ardelyx, Inc. | 2 | $39 |
| Eisai Inc. | 2 | $35 |
| Abbott | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,985 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $189,835 |
| EliquisApixaban | 153 | $121,502 |
| JardianceEmpagliflozin | 147 | $111,296 |
| LinzessLinaclotide | 126 | $77,268 |
| MounjaroTirzepatide | 61 | $66,866 |
| RybelsusSemaglutide | 54 | $57,649 |
| FarxigaDapagliflozin Propanediol | 83 | $54,771 |
| XareltoRivaroxaban | 57 | $35,074 |
| TrulancePlecanatide | 55 | $34,932 |
| JanuviaSitagliptin Phosphate | 55 | $34,598 |
| MyrbetriqMirabegron | 45 | $27,346 |
| TrulicityDulaglutide | 16 | $23,262 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,779 |
| WegovySemaglutide | 15 | $19,887 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $19,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,592 | $267,371248 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $355 | $147,000213 claims |
| PfizerEliquis, Premarin | $228 | $125,607173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $838 | $90,12877 claims |
| AbbVieLinzess, Creon | $686 | $86,407137 claims |
| AstraZenecaFarxiga, Brilinta | $598 | $67,527103 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $211 | $41,52180 claims |
| Johnson & JohnsonXarelto | $279 | $35,07457 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $444 | $34,93255 claims |
| MerckJanuvia | $208 | $34,59855 claims |
| NovartisEntresto | $199 | $12,76715 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $20 | $6,452159 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Kinston
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.